Tianjin Pharmaceutical da REN Tang Group Corporation Limited Stock: price and insider trades · Singapore
No insider purchase over the last 90 days. The latest, by Guo Min, was filed 04 Aug 2026.
Tianjin Pharmaceutical da REN Tang Group Corporation Limited: what insiders have been doing
Tianjin Pharmaceutical da REN Tang Group Corporation Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SGX. 3 insiders have disclosed 4 filings since 22 October 2025.
Not one open-market sale was filed. On the buying side, 3 insiders reported 4 purchases totalling €23. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €6 by Guo Min, published on 4 August 2026, equal to 0.0000% of the market capitalisation. The buyers include 2 major shareholders and 1 chief executive.
For context, the typical company on the same exchange (median of 394 companies) published 6 filings over the same period, against 4 filings here. Since 2018, the database holds 10 purchases and no sales by insiders of the company.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 4 August 2026, which is 96 days ago. Between a trade and the moment it shows up on SGX, the median delay is 1 day. Until a filing is published, the market cannot know about the trade.
These figures are compiled from regulatory filings published by SGX. They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -2.9%Entry US$2.73 · Close 19 Oct 2026 US$2.65
- -21.6%Entry US$3.38 · Close 19 Oct 2026 US$2.65
- -21.6%Entry US$3.38 · Close 19 Oct 2026 US$2.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 9 shares@ SGD 1.000.0000% mcap100.0% of flowShareSGX-STISIN CNE100000924SGX:PHARI82HES0BJB02Canonical exit: 2 Nov 2026 (T+90)
- 8 shares@ SGD 1.00100.0% of flowShareSGX-STISIN CNE100000924SGX:NTGH7M4XYRFTTVKMCanonical exit: 5 May 2026 (T+90)
- 9 shares@ SGD 1.0049.6% of flowShareSGX-STISIN CNE100000924SGX:5GG1NX8R9GAEOGK5Canonical exit: 5 May 2026 (T+90)
- 8 shares@ SGD 1.00100.0% of flowShareSGX-STISIN CNE100000924SGX:J3IA448V89XIRI5OCanonical exit: 5 May 2026 (T+90)
- 4 shares@ SGD 1.00100.0% of flowShareSGX-STISIN CNE100000924SGX:YRTV5VYMVA5B3DNJCanonical exit: 21 Feb 2024 (T+90)
- 4 shares@ SGD 1.0049.9% of flowShareSGX-STISIN CNE100000924SGX:TZPWDQBJ5OLE2C6HCanonical exit: 5 Nov 2023 (T+90)
- 4 shares@ SGD 1.0050.1% of flowShareSGX-STISIN CNE100000924SGX:E2OWP642M8L85M3DCanonical exit: 2 Nov 2023 (T+90)
- 4 shares@ SGD 1.00100.0% of flowShareSGX-STISIN CNE100000924SGX:12YFLTF87NR9WLG8Canonical exit: 24 Jun 2021 (T+90)
- 4 shares@ SGD 1.00100.0% of flowShareSGX-STISIN CNE100000924SGX:OD4UV4F6QH6YI3F3Canonical exit: 24 Jun 2021 (T+90)
- 10 shares@ SGD 1.0050.3% of flowShareSGX-STISIN CNE100000924SGX:W436OQCDJXZ58SGJ
- 10 shares@ SGD 1.0049.7% of flowShareSGX-STISIN CNE100000924SGX:PIXFA2R98F9G8Z3E
- 8,530 sharesShareSGX-STISIN CNE100000924SGX:QINM4LPXVYTTLQN7Canonical exit: 14 Jan 2019 (T+90)
12 of 12 declarations
About Tianjin Pharmaceutical da REN Tang Group Corporation Limited
Tianjin Pharmaceutical da REN Tang Group Corporation Limited is a company engaged in the manufacturing and distribution of pharmaceutical products in China. It primarily operates in the health and wellness market.
